ASH 2021 | Safety and efficacy of CPX-351 in newly diagnosed AML patients under the age of 60
Eunice Wang
• 13 Dec 2021
In this video, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses results from a study which analyzed the safety and efficacy of CPX-351 in the treatment of patients with newly diagnosed secondary acute myeloid leukemia (AML) under the age of 60 years old. Dr Wang first explains the results from a previous Phase III trial which found CPX-351 to be effective in the treatment of patients over the age of 60, and then goes on to discuss the results of the current analysis, as well as possible explanations for the findings. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
